DCLK1 and neoplasm: Targeting DCLK1 using small molecules, natural, synthetic inhibitors, and technologies such as the use of mAbs, CRISPR/Cas9, and by silencing siRNA and shRNA has shown promising results in reducing cancer relapse of the tumor.